ASX:ILAPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
ISLAND PHARMACEUTICALS ORD
$0.355
$0.005 (1.39%)
Day Range
$0.350 - $0.360
52 Week Range
$0.130 - $0.630
Volume
225.73K
Avg Volume (10D)
91.13K
Market Cap
$105.05M
Price Chart
Market Statistics
Open$0.360
Previous Close$0.360
Day High$0.360
Day Low$0.350
52 Week High$0.630
52 Week Low$0.130
Valuation
Market Cap105.05M
Shares Outstanding295.92M
Price to Book13.91
Trading Activity
Volume225.73K
Value Traded80.66K
Bid$0.350 × 30,714
Ask$0.370 × 5,589
Performance
1 Day0.00%
5 Day-2.63%
13 Week-5.13%
52 Week117.65%
YTD-13.95%
Technical Indicators
RSI (14)40.41
50-Day SMA$0.384
200-Day SMA$0.372
Latest News
Biotechnology
Island Pharma Expands Antiviral Pipeline with Burnet Institute Collaboration and NHMRC Funding
Island Pharma expands antiviral pipeline with Burnet Institute; NHMRC grant of over $780k to back ISLA-101, accelerating Galidesivir MVD program.
1 min read
Biotechnology
Island Pharma Partners with USAMRIID and Geneva Foundation for Galidesivir under FDA Animal Rule
Island Pharma signs a 3-year CRADA with USAMRIID and Geneva Foundation to fast-track Galidesivir for Marburg under FDA Animal Rule, eyeing NDA.
1 min read
Biotechnology
Island Pharmaceuticals Raises $9m to Fund Clinical Development as FDA Approves Galidesivir Pathway
Island Pharmaceuticals (ASX: ILA) secures FDA Animal Rule path for galidesivir and $9m funding to fast-track two-stage trials and US govt procurement potential.
1 min read
Biotechnology
Island Pharmaceuticals and Texas Biomed to Conduct Non-Human Primate Studies Using Antiviral Drug Galidesivir
Island Pharmaceuticals (ASX: ILA) has secured a master service agreement with Texas Biomedical Research Institute to support the development of lead antiviral molecule galidesivir.
1 min read